You are here

Article Text

Article menu
Download PDFPDF
Neurology
Beyond conventional therapies: IVIG in treating severe fingolimod-rebound in a postpartum patient with MS
  1. Abdulkadir Tunç1,
  2. Alihan Abdullah AKBAŞ1,
  3. Beyzanur Bozkurt1 and
  4. Samet Oncel2
  1. 1Department of Neurology, Sakarya University Faculty of Medicine, Sakarya, Turkey
  2. 2Department of Neurology, Ministry of Health Sakarya Education and Research Hospital, Adapazari, Sakarya, Turkey
  1. Correspondence to Dr Abdulkadir Tunç; drkadirtunc{at}hotmail.com

Abstract

This case report details a female patient with multiple sclerosis in her 30s, who experienced a significant fingolimod rebound syndrome post partum, characterised by worsening neurological symptoms and severe demyelinating lesions. Traditional treatments, including steroids and plasmapheresis, were ineffective. However, the introduction of intravenous immunoglobulin (IVIG) led to remarkable improvement in her symptoms and disability status. This case highlights the complex immunological changes associated with fingolimod cessation and underscores IVIG’s potential as a valuable treatment in managing such rebounds.

  • Multiple sclerosis
  • Drugs and medicines

https://doi.org/10.1136/bcr-2024-259932

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors All authors were responsible for drafting of the text, sourcing and editing of clinical images, investigation results, drawing original diagrams and algorithms, and critical revision for important intellectual content. All authors gave final approval of the manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.